 |
(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Biliary tract cancer |
| EU Market Approval | EU |
| EU Designation Date | 2016-05-30 00:00:00 |
| Sponsor | QRC Consultants Ltd |
